API Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating

Research and Markets has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015–2019" report to their offering.

The API market in the US to grow at a CAGR of 7% over the period 2014-2019.

A major trend upcoming in the API market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy.

According to the report, one of the key drivers contributing to the growth of the API market in the US is the strong preference for generic drugs compared with innovative or branded drugs. The use of generic equivalents is preferred to innovative drugs, with countries encouraging doctors and pharmacists to prescribe such equivalents.

Further, the report states that stringent regulations are one of the major challenges that the market faces. Vendors are required to comply with elaborate procedures prior to product commercialization. For instance, compliance with GMP requirements increases costs for vendors.

Key Vendors

• Abbott Laboratories
• Aurobindo Pharma
• Mylan
• Teva Pharmaceutical Industries

Other Prominent Vendors

Albemarle
• Aptuit
• BASF
• Biocon
• Boehringer Ingelheim
• Cambrex
• Cipla
• Dr. Reddy's Laboratories
• Hospira
• Lonza Group
• Novartis
• Pfizer
• Sigma-Aldrich
• Sun Pharmaceutical Industries

Key Topics Covered:

1. Executive Summary
2. List of Abbreviations
3. Scope of the Report
4. Market Research Methodology
5. Introduction
6. Market Landscape
7. API Market in the US
8. Market Segmentation by Type of Production Process
9. Market Segmentation by Type of Product
10. Market Segmentation by Type of Players
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
19. Key Vendor Analysis